First-in-human study underway evaluating anti-CD36 monoclonal antibody designed to restore metabolic fitness in exhausted T cells, reduce immunosuppressive cells, and enhance antitumor immunity ...
Sleep apnea affects nearly one billion people worldwide and causes repeated episodes of oxygen deprivation during the night, ...
XCells Biotechnologies USA, Inc. ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem ...
You probably heard it in biology class: mitochondria are the powerhouse of the cell. You memorized it, put it on your test, and moved on. But for Dr. Chad Frasier, associate professor in the ...
XCells Biotechnologies USA Inc. has delivered over 500 characterized induced pluripotent stem cell lines as part of a multi-year collaboration with a global biotechnology company.
The first cell rejuvenation therapy is set to enter clinics, testing if aging cells can be reset to a younger, healthier ...
British scientist says humans could live 20,000 years through DNA reprogramming and cellular repair technology that ...
Pancreatic cancer is one of the most aggressive and deadly forms of cancer. It is often diagnosed at a late stage, when the disease has already spread to other organs such as the liver. Because of ...
If federal employees are required to report to work, safeguard the public and keep the country running, they must be paid on time.
However, definitive diagnosis evaded him, "We didn't go out and get a PET scan or a spinal tap, which would actually reveal if you actually have the plaques, because those tests were not covered by my ...
Katsch has mapped a clear timeline to 2030, encompassing infrastructure deployment, strategic global partnerships, and capital strategies designed to scale the platform to serve billions. The ambition ...
Immunotherapy has revolutionized cancer treatment, yet response rates remain highly variable across tumor types and individual patients. Increasing evidence ...